Wechselwirkungen · Kaftrio
Kaftrio 60 mg/40 mg/80 mg granules in sachet Kaftrio 75 mg/50 mg/100 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 41
HOS-145679 · Präparat HOS-099389
CYP3A inducers ELX, TEZ and IVA are substrates of CYP3A (IVA is a sensitive substrate of CYP3A). Concomitant use of strong CYP3A inducers may result in reduced exposures and thus reduced IVA/TEZ/ELX efficacy. Co-administration of IVA with rifampicin, a strong CYP3A inducer, significantly decreased IVA area under the curve (AUC) by 89%. ELX and TEZ exposures are also expected to decrease during co-administration with strong CYP3A inducers; therefore, co-administration with strong CYP3A inducers is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T16:15:00Z · SHA-256 04121cac1535ad5982d6257c33a1777a08c5914a9fce488aee1208cd9e01ad69 · Passage a3926bc16b7e1121b307e9c10bc01bc24f2252ecf7fd097182a28b79d4df3266 · Zeichen 74–610 im Abschnitt